MiRagen raises $40.7 million, goes public with Signal Genetics merger

BOULDER — Clinical-stage biopharmaceutical company MiRagen Therapeutics Inc. has completed its merger with a publicly traded California company, raising $40.7 million in private equity financing just prior to the deal. MiRagen begins trading Tuesday on the Nasdaq exchange under the ticker symbol “MGEN.”

The Boulder-based company reported the private funding in a Regulation D filing with the U.S. Securities and Exchange Commission, Feb. 13.
The new equity financing came from current and new miRagen investors, including Fidelity Management and Research Co., Brace Pharma…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!